Inclusion Criteria:  Is on a stable regimen of a single background antihypertensive agent for at least 8 weeks and a second antihypertensive agent is warranted at the time of screening; Has a mean seated systolic blood pressure (SBP) ≥ 140 mmHG; Demonstrates they are able to be adherent to the study drug and their anti-hypertensive medication during a run-in period If taking SGLT2 inhibitor, the regimen must be stable for at least 8 weeks prior to randomization; and Agrees to comply with the contraception and reproduction restrictions of the study;  Exclusion Criteria:  Has a mean seated systolic blood pressure (SBP) ≥180 mmHG; Has a body mass index (BMI) >50 kg/m2; Is using alpha or beta blockers for any primary indication other than systemic hypertension (eg, migraine headache); Is not willing or not able to discontinue an MRA or potassium sparing diuretic as part of an existing antihypertensive regimen; Has documented estimated eGFR <30 mL/min/1.73m2; Has known and documented New York Heart Association stage III or IV chronic heart failure; Has had a stroke, transient ischemic attack, hypertensive encephalopathy, acute coronary syndrome, or hospitalization for heart failure within 6 months before screening; Major cardiac surgery within 6 months before Screening; Has chronic permanent atrial fibrillation; Has uncontrolled diabetes with glycosylated hemoglobin >10% at Screening; Has planned dialysis or kidney transplantation planned during the course of the study; Prior solid organ transplant and/or cell transplants; Sodium <130 mEq/L; Potassium <3.5 mEq/L; Potassium >5 mEq/L; Is positive for HIV antibody, hepatitis C virus RNA, or hepatitis B surface antigen; Has typical consumption of ≥14 alcoholic drinks weekly;